The IPO of Bicara Therapeutics Inc is a significant event as it marks the company's entry into the public market. The pricing of shares between $16.00 and $18.00 suggests a valuation that investors will closely watch. The focus on bifunctional therapies for solid tumors could attract interest from investors in the biotech sector. The insider lock-up period of 180 days is standard, but it means that insiders cannot sell their shares immediately, which could stabilize the stock price in the short term.